Literature DB >> 33688961

National Trends in the Use of Neoadjuvant Therapy Before Cancer Surgery in the US From 2004 to 2016.

Christopher T Aquina1, Aslam Ejaz1, Allan Tsung1, Timothy M Pawlik1, Jordan M Cloyd1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33688961      PMCID： PMC7948056          DOI： 10.1001/jamanetworkopen.2021.1031

Source DB:  PubMed          Journal:  JAMA Netw Open        ISSN： 2574-3805


× No keyword cloud information.
  6 in total

1.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

Review 2.  Using the National Cancer Database for Outcomes Research: A Review.

Authors:  Daniel J Boffa; Joshua E Rosen; Katherine Mallin; Ashley Loomis; Greer Gay; Bryan Palis; Kathleen Thoburn; Donna Gress; Daniel P McKellar; Lawrence N Shulman; Matthew A Facktor; David P Winchester
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

3.  Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.

Authors:  Joel Shapiro; J Jan B van Lanschot; Maarten C C M Hulshof; Pieter van Hagen; Mark I van Berge Henegouwen; Bas P L Wijnhoven; Hanneke W M van Laarhoven; Grard A P Nieuwenhuijzen; Geke A P Hospers; Johannes J Bonenkamp; Miguel A Cuesta; Reinoud J B Blaisse; Olivier R C Busch; Fiebo J W Ten Kate; Geert-Jan M Creemers; Cornelis J A Punt; John Th M Plukker; Henk M W Verheul; Ernst J Spillenaar Bilgen; Herman van Dekken; Maurice J C van der Sangen; Tom Rozema; Katharina Biermann; Jannet C Beukema; Anna H M Piet; Caroline M van Rij; Janny G Reinders; Hugo W Tilanus; Ewout W Steyerberg; Ate van der Gaast
Journal:  Lancet Oncol       Date:  2015-08-05       Impact factor: 41.316

Review 4.  Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis.

Authors: 
Journal:  Lancet       Date:  2003-06-07       Impact factor: 79.321

5.  Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Jordan M Cloyd; Victor Heh; Timothy M Pawlik; Aslam Ejaz; Mary Dillhoff; Allan Tsung; Terence Williams; Laith Abushahin; John F P Bridges; Heena Santry
Journal:  J Clin Med       Date:  2020-04-15       Impact factor: 4.241

Review 6.  Neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma: The need for patient-centered research.

Authors:  Jordan M Cloyd; Allan Tsung; John Hays; Celia E Wills; John Fp Bridges
Journal:  World J Gastroenterol       Date:  2020-01-28       Impact factor: 5.742
  6 in total
  5 in total

1.  Characterizing the patient experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma: A qualitative study.

Authors:  Lena Stevens; Zachary J Brown; Ryan Zeh; Christina Monsour; Sharla Wells-Di Gregorio; Heena Santry; Aslam M Ejaz; Timothy Michael Pawlik; Jordan M Cloyd
Journal:  World J Gastrointest Oncol       Date:  2022-06-15

2.  Impact of care fragmentation on the outcomes of patients receiving neoadjuvant and adjuvant therapy for pancreatic adenocarcinoma.

Authors:  Zachary J Brown; Hanna E Labiner; Chengli Shen; Aslam Ejaz; Timothy M Pawlik; Jordan M Cloyd
Journal:  J Surg Oncol       Date:  2021-10-02       Impact factor: 2.885

3.  Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic ductal adenocarcinoma.

Authors:  Lena Schreiber; Ryan Zeh; Christina Monsour; Aslam Ejaz; Allan Tsung; Timothy M Pawlik; Eric Miller; Anne Noonan; Somashekar G Krishna; Heena Santry; Jordan M Cloyd
Journal:  HPB (Oxford)       Date:  2021-10-25       Impact factor: 3.842

4.  Systemic Therapy Is Associated with Improved Oncologic Outcomes in Resectable Stage II/III Intrahepatic Cholangiocarcinoma: An Examination of the National Cancer Database over the Past Decade.

Authors:  Rebecca Marcus; Wade Christopher; Jennifer Keller; Sean Nassoiy; Shu-Ching Chang; Melanie Goldfarb; Ronald Wolf; Zeljka Jutric
Journal:  Cancers (Basel)       Date:  2022-09-03       Impact factor: 6.575

5.  Neoadjuvant chemotherapy improves overall survival in resectable colorectal liver metastases patients with high clinical risk scores-- A retrospective, propensity score matching analysis.

Authors:  Feng-Lin Chen; Yan-Yan Wang; Wei Liu; Bao-Cai Xing
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.